Cagrilintide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 3 Apr 2023: Trial started, NCT05813925
  2. 14 Apr 2023: Trial registered, NCT05813925
  3. 15 Aug 2023: Trial started, NCT05996848
  4. 18 Aug 2023: Trial registered, NCT05996848

The trials

NCT05813925: A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

State
Completed
Phase
Phase 3
People
331 taking part
Started
3 Apr 2023
Primary completion
17 Jan 2025
Arms
CagriSema 2.4 mg/2.4 mg
Results
None posted
  1. 3 Apr 2023: Trial started
  2. 14 Apr 2023: Trial registered
  3. 7 Mar 2025: Trial completed

NCT05996848: A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

State
Completed
Phase
Phase 3
People
300 taking part
Started
15 Aug 2023
Primary completion
6 Jan 2025
Arms
CagriSema
Results
None posted
  1. 15 Aug 2023: Trial started
  2. 18 Aug 2023: Trial registered
  3. 22 Feb 2025: Trial completed

NCT06131372: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

State
Completed
Phase
Phase 2
People
626 taking part
Started
1 Apr 2024
Primary completion
24 Sep 2025
Arms
Cagrilintide
Results
None posted
  1. 14 Nov 2023: Trial registered
  2. 1 Apr 2024: Trial started
  3. 6 Nov 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.